{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:41:32Z","timestamp":1789213292575,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.coph.2022.102241","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T12:03:42Z","timestamp":1653134622000},"page":"102241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Emerging strategies for treating gout"],"prefix":"10.1016","volume":"65","author":[{"given":"Edward M.","family":"Huddleston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo L.","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102241_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/acr.22585","article-title":"Study for updated gout classification criteria: identification of features to classify gout","volume":"67","author":"Taylor","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102241_bib2","first-page":"1","article-title":"The economic burden of uncontrolled gout: how controlling gout reduces cost","volume":"22","author":"Flores","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.coph.2022.102241_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semarthrit.2015.02.004","article-title":"The economic burden of gout: a systematic review","volume":"45","author":"Rai","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102241_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coph.2022.102241_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102241_bib7","doi-asserted-by":"crossref","first-page":"800 e813","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.coph.2022.102241_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","article-title":"Frequency and risk factors of gout flares in a large population-based cohort of incident gout","volume":"50","author":"Rothenbacher","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102241_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.coph.2022.102241_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-018-1558-3","article-title":"Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities","volume":"20","author":"Sun","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102241_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.coph.2022.102241_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.coph.2022.102241_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/1756-185X.14205","article-title":"The current role of NLRP3 inflammasome polymorphism in gout susceptibility","volume":"24","author":"Clavijo-Cornejo","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.coph.2022.102241_bib14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coph.2022.102241_bib15","first-page":"290","article-title":"Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study","volume":"41","author":"Hosoya","year":"2016","journal-title":"J\u00a0Clin Pharm Therapeut"},{"key":"10.1016\/j.coph.2022.102241_bib16","first-page":"151","article-title":"Chapter eleven - urate crystal deposition disease and gout\u2014new therapies for an old problem","volume":"49","author":"Girardet","year":"2014","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.coph.2022.102241_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s40801-022-00291-w","article-title":"Evaluation of the effect of topiroxostat on renal function in patients with hyperuricemia: STOP-C study, a retrospective observational cohort study","author":"Tamiya","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.coph.2022.102241_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","article-title":"Safety and tolerability of available urate-lowering drugs: a critical review","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.coph.2022.102241_sref19","series-title":"Arthritis rheumatol","article-title":"Phase 2 study results from a randomized, double-blind, placebo-controlled, dose-finding study to evaluate efficacy and safety of tigulixostat, a novel non-purine selective xanthine oxidase inhibitor, in gout patients with hyperuricemia","volume":"vol. 73","author":"Terkeltaub","year":"2021"},{"key":"10.1016\/j.coph.2022.102241_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(10)60665-4","article-title":"Gout therapeutics: new drugs for an old disease","volume":"377","author":"Burns","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102241_bib22","series-title":"Arthritis rheumatol","article-title":"AR882, a potent and selective uricosuric agent, significantly reduced serum urate in patients with gout in a phase 2a study","volume":"vol. 72","author":"Yeh","year":"2020"},{"key":"10.1016\/j.coph.2022.102241_bib23","unstructured":"Phase 2B evaluation of efficacy and safety of AR882 in gout patients - full text view. Full Text View - ClinicalTrials.gov. Edited by."},{"key":"10.1016\/j.coph.2022.102241_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.161062","article-title":"The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout","volume":"44","author":"Steinberg","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib25","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A\u00a0randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib26","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.coph.2022.102241_sref27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","article-title":"Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout","volume":"22","author":"Ishikawa","year":"2021","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.coph.2022.102241_bib28","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102241_sref29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/annrheumdis-2020-eular.4642","article-title":"THU0410 companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout","volume":"79","author":"Rainey","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102241_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coph.2022.102241_sref33","doi-asserted-by":"crossref","first-page":"569215","DOI":"10.3389\/fmed.2020.569215","article-title":"Oral treatment with an engineered uricase, ALLN-346, reduces hyperuricemia, and uricosuria in urate oxidase-deficient mice","volume":"7","author":"Pierzynowska","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.coph.2022.102241_bib34","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-019-1834-x","article-title":"Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression","volume":"21","author":"Cleophas","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coph.2022.102241_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","author":"Janssen","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.coph.2022.102241_sref37","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A\u00a0randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3899\/jrheum.181018","article-title":"Use of anakinra in hospitalized patients with crystal-associated arthritis","volume":"46","author":"Liew","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.coph.2022.102241_bib39","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.33412","article-title":"Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2022.102241_bib40","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2022.102241_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ph11020051","article-title":"Side effects and interactions of the xanthine oxidase inhibitor febuxostat","volume":"11","author":"Jordan","year":"2018","journal-title":"Pharmaceuticals"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:23Z","timestamp":1761461843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":41,"alternative-id":["S1471489222000686"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102241","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging strategies for treating gout","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102241"}}